Related Experiment Video
Updated: May 15, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Treatment of diffuse large B cell lymphoma.
1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea. jykwak@jbnu.ac.kr
The Korean Journal of Internal Medicine
|December 28, 2012
Summary
Diffuse large B cell lymphoma (DLBCL), a common non-Hodgkin lymphoma, shows relapse in 30% of patients despite rituximab-chemotherapy. New genetic subtypes offer potential for targeted therapies and improved prognoses.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Diffuse large B cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma globally.
- Current standard treatment combines chemotherapy with the monoclonal antibody rituximab, significantly improving outcomes.
- However, approximately 30% of patients relapse after this therapy, highlighting the need for improved treatment strategies.
Purpose of the Study:
- To investigate the heterogeneity of DLBCL.
- To explore the clinical implications of newly identified DLBCL subtypes based on gene expression profiling.
- To identify potential biomarkers and therapeutic targets for future DLBCL treatments.
Main Methods:
- Gene expression profiling to classify DLBCL subtypes.
- Analysis of clinical behaviors and prognoses associated with different DLBCL subtypes.
- Review of current treatment outcomes and relapse rates.
Main Results:
- DLBCL is recognized as a heterogeneous disease with distinct subtypes.
- Gene expression profiling has identified subtypes with varying clinical behaviors and prognoses.
- Despite advances, a significant proportion of patients experience treatment relapse.
Conclusions:
- DLBCL heterogeneity necessitates personalized treatment approaches.
- Genetic information is crucial for identifying prognostic biomarkers and therapeutic targets.
- Future DLBCL management will likely incorporate molecular subtyping for tailored therapies.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...